Skip to content

house · Committee report

H. Rept. 118-647

TO AMEND TITLE 38, UNITED STATES CODE, TO DIRECT THE SECRETARY OF VETERANS AFFAIRS TO REPORT ON WHETHER THE SECRETARY WILL INCLUDE CERTAIN PSYCHEDELIC DRUGS IN THE FORMULARY OF THE DEPARTMENT OF VETERANS AFFAIRS

2024-09-06

Committees

Associated legislation

Text

Purpose and Summary

H.R. 7347, ``To amend Title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs,'' was introduced by Representative Derrick Van Orden of Wisconsin on February 14, 2024. H.R. 7347 would require the U.S. Department of Veterans Affairs (VA) to submit a report to Congress no later than 180 days after the U.S. Food and Drug Administration (FDA) approval of a psychedelic drug, outlining whether or not VA is choosing to include the drug in the VA formulary, as well as justifications as to why or why not.

Background and Need for Legislation

Section 1. Reporting of Determination of the Secretary of Veterans Affairs Whether to Include Newly Approved or Licensed Psychedelic Drugs in the Formulary of the Department of Veterans Affairs Under current law, psychedelic assisted therapy and the drugs associated with it are only authorized for use in clinical trials to study the effects of these drugs on patients with severe suicidality and Post Traumatic Stress Disorder (PTSD). This bill would require VA to send a report to the House and Senate Committees on Veterans' Affairs on whether VA has decided to include psychedelics in the VA formulary if the FDA approves the drug, as part of the list of approved drugs for prescription and clinical use for veterans struggling with PTSD, thoughts of suicide, or other conditions that may benefit from the use of the approved drug as determined by the veterans' primary care physician. The VA formulary is a list of approved drugs for prescription and clinical use approved by the Department. As the FDA continues to study and approve psychedelic drugs for clinical use, the Committee recognizes the potential benefits these treatments have in saving veteran lives and mitigating some of the symptoms of PTSD. VA's ongoing clinical trials are an important part of the research which can inform the benefits of the use of these drugs. According to VA's 2023 Annual Suicide Prevention Report, around 17 veterans per day die by suicide.\1\ Some of VA's research at local medical facilities show that psychedelic assisted therapy has strong positive effects on the treatment of PTSD. This indicates that the use of psychedelics has the potential to significantly reduce suicides. However, if these drugs are not placed on the VA formulary, VA providers may not be able to consider the use of the drug in the veterans' treatment plan. --------------------------------------------------------------------------- \1\2023 National Veteran Suicide Prevention Annual Report, Department of Veterans Affairs, 2023, https://www.mentalhealth.va.gov/ docs/data-sheets/2023/2023-National-Veteran-Suicide-Prevention-Annual- Report-FINAL-508.pdf. --------------------------------------------------------------------------- In 2023, the Committee conducted site visits to the Bronx VA Medical Center, New York University (NYU), and Johns Hopkins University (JHU) to meet with researchers at the forefront of ongoing clinical trials aimed at addressing severe suicidality and depression with psychedelic assisted therapy. Committee staff learned that NYU has conducted extensive trials with Methylenedioxymethamphetamine (MDMA). The results of one trial indicate that 88% of MDMA assisted therapy trial participants have significantly reduced PTSD symptoms after their third and final dosing session, with 67% achieving remission.\2\ The duration of this treatment spans three months, with patients being monitored by their physician throughout the duration of the trial. Studies show that psychedelic assisted therapy may also have tremendous potential in addressing alcoholism and substance use disorders. Researchers at NYU have seen an 83% reduction in heavy drinking among patients undergoing psilocybin assisted therapy treatment, with 48% stopping drinking altogether.\3\ --------------------------------------------------------------------------- \2\MDMA Assisted Therapy for PTSD Completion of Phase 3 Study, Psychiatric Times, 2022, https://www.psychiatrictimes.com/view/mdma- assisted-therapy-for-ptsd-completion-of-phase-3-study. \3\Psychedelic Drug Therapy May Help Treat Alcohol Addiction, NYU Langone Health, 2022, https://nyulangone.org/news/psychedelic-drug- therapy-may-help-treat-alcohol-addiction. --------------------------------------------------------------------------- Based upon the results of those trials, the Committee believes that time is of the essence in getting these therapies approved for wide-scale use at VA upon FDA approval, which could happen as soon as the Fall of 2024. The Committee believes this bill would put pressure on VA to establish a timeline on the availability of these life saving drugs so that proper oversight can be conducted, as the Committee does not want VA to fall behind the private sector in the availability of these breakthrough treatments that could be available to veterans through VA.

Hearings

On March 21, 2024, the subcommittee on Health held a legislative hearing on H.R. 7347. The following witnesses testified: The Honorable Mike Bost, U.S. House of Representatives, Illinois 12th; The Honorable Chris Deluzio, U.S. House of Representatives, Pennsylvania 17th; The Honorable Jack Bergman, U.S. House of Representatives, Michigan 1st; The Honorable Greg Murphy, U.S. House of Representatives, North Carolina 3rd; The Honorable Derrick Van Orden, U.S. House of Representatives, Wisconsin 3rd; The Honorable Nick LaLota, U.S. House of Representatives, New York 1st; The Honorable Debbie Dingell, U.S. House of Representatives, Michigan 6th; The Honorable Lauren Underwood, U.S. House of Representatives, Illinois 14th; Dr. Ajit Pai, Executive Director, Office of Rehabilitation and Prosthetic Services, Veterans Health Administration, U.S. Department of Veterans Affairs; Dr. Michael Brennan, Executive Director, Office of Construction and Facilities Management, U.S. Department of Veterans Affairs; Dr. Wendy Tenhula, Deputy Chief Research and Development Officer, Office of Research and Development, Veterans Health Administration, U.S. Department of Veterans Affairs; Dr. David Perry Chief Officer, Workforce Management and Consulting, Veterans Health Administration, U.S. Department of Veterans Affairs; Mr. Jon Retzer, Assistant National Legislative Director, Disabled American Veterans; Mr. Roscoe Butler, Senior Health Policy Advisor, Paralyzed Veterans of America; Ms. Brittany Elliot, Veteran (USMC), Advocate; Ms. Melissa Bryant, Chair, Board of Directors, Minority Veterans of America. The following individuals and organizations submitted statements for the record: Wounded Warrior Project, Treat Now, Superior Ambulance. Subcommittee Consideration On April 16, 2024, the Health Subcommittee met in an open markup session, a quorum being present, and ordered H.R. 7347 to be reported favorably to the Full Committee by voice vote.

Committee Consideration

On May 1, 2024, the full Committee met in open markup session, a quorum being present, and ordered H.R. 7347 be reported favorably to the House of Representatives by voice vote. A motion by Ranking Member Takano of California to report H.R. 7347 favorably to the House of Representatives was agreed to by voice vote.

Committee Votes

In compliance with clause 3(b) of rule XIII of the Rules of the House of Representatives, no recorded votes were taken with ordering H.R. 7347 reported to the House. Committee Oversight Findings In compliance with clause 3(c)(1) of rule XIII and clause (2)(b)(1) of rule X of the Rules of the House of Representatives, the Committee's oversight findings and recommendations are reflected in the descriptive portions of this report. Statement of General Performance Goals and Objectives In accordance with clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee's performance goals and objectives of H.R. 7347 are to provide a report to Congress on the plans of the Department of Veterans Affairs to include psychedelic drugs in the formulary. Earmarks and Tax and Tariff Benefits H.R. 7347 does not contain any Congressional earmarks, limited tax benefits, or limited tariff benefits as defined in clause 9 of rule XXI of the Rules of the House of Representatives. Committee Cost Estimate The Committee adopts as its own the cost estimate on H.R. 7347 prepared by the Director of the Congressional Budget Office. Budget Authority and Congressional Budget Office Cost Estimate H.R. 7347 would require the Department of Veterans Affairs (VA) to report to the Congress whenever a decision is made about whether to include on VA's prescription formulary, psychedelic drugs that have been approved by the Food and Drug Administration. Under current law, VA publicizes its decisions about what to include in the department's formulary, and to date, no psychedelic drugs have been approved for medical use by the Food and Drug Administration. CBO estimates that satisfying the requirement to report to the Congress would cost less than $500,000 over the 2024-2034 period. The CBO staff contact for this estimate is Matt Schmit. The estimate was reviewed by Christina Hawley Anthony, Deputy Director of Budget Analysis. Phillip L. Swagel, Director, Congressional Budget Office. Federal Mandates Statement Section 423 of the Congressional Budget and Impoundment Control Act (as amended by Section 101(a)(2) of the Unfunded Mandate Reform Act, P.L. 104-4) is inapplicable to H.R. 7347. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act would be created by H.R. 7347. Applicability to Legislative Branch The Committee finds that H.R. 7347 does not relate to the terms and conditions of employment or access to public services or accommodation within the meaning of section 102(b)(3) of the Congressional Accountability Act. Statement on Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee finds that no provision of H.R. 7347 establishes or reauthorizes a program of the Federal Government known to be duplicative of another Federal program, a program that was included in any report from the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139, or a program related to a program identified in the most recent Catalog of Federal Domestic Assistance. Section-by-Section Analysis of the Legislation Section 1. Reporting of determination of the Secretary of Veterans Affairs whether to include newly approved or licensed psychedelic drugs in the formulary of the Department of Veterans Affairs This section would amend Chapter 81 of title 38, United States Code, by inserting, a new section Sec. 8125A, which would require, no later than 180 days after a psychedelic drug is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary to submit to the House and Senate Committees on Veterans' Affairs a report regarding such drug, that includes the determination of the Secretary whether to include such drug in the formulary of the Department, and the justification of the Secretary for such determination. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, existing law in which no change is proposed is shown in roman): Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (new matter is printed in italics and existing law in which no change is proposed is shown in roman): TITLE 38, UNITED STATES CODE * * * * * * * PART VI--ACQUISITION AND DISPOSITION OF PROPERTY * * * * * * * CHAPTER 81--ACQUISITION AND OPERATION OF HOSPITAL AND DOMICILIARY FACILITIES; PROCUREMENT AND SUPPLY; ENHANCED-USE LEASES OF REAL PROPERTY * * * * * * * Sec. * * * * * * * SUBCHAPTER II--PROCUREMENT AND SUPPLY * * * * * * * 8125A. Reporting of determination whether to include newly approved or licensed psychedelic drugs in the formulary of the Department. * * * * * * * SUBCHAPTER II--PROCUREMENT AND SUPPLY * * * * * * * SEC. 8125A. REPORTING OF DETERMINATION WHETHER TO INCLUDE NEWLY APPROVED OR LICENSED PSYCHEDELIC DRUGS IN THE FORMULARY OF THE DEPARTMENT Not later than 180 days after a psychedelic drug is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary shall submit to the Committees on Veterans' Affairs of the Senate and House of Representatives a report regarding such drug, that includes-- (1) the determination of the Secretary whether to include such drug in the formulary of the Department; and (2) the justification of the Secretary for such determination. * * * * * * *

Source: https://api.congress.gov/v3/committee-report/118/hrpt/647